摘要
结直肠癌(CRC)是一种异质性疾病,在分子癌变和形态癌变多步途径方面都是如此。由于不同致癌途径所涉及的遗传和表观遗传机制的差异,CRC内存在着相当大的异质性。对肿瘤病理生理学的深入了解是发展现代成功的治疗转移性大肠癌的有效手段所必需的。在过去的5年中,人们对结直肠癌的分子分类产生了极大的兴趣,因为它对于预测预后和指导个性化治疗都具有重要的临床意义。最近,结直肠癌亚型联合会确定了四种共同的分子亚型,即CRC中的CMS 1-4;然而,利用分子特征对CRC进行分层以用于预后和临床条件下的预测目的尝试取得了有限的成功。在这篇综述中,我们重点讨论了包括特定突变在内的CRC的分子定义亚型,并讨论了对目前和未来转移性CRC患者进行治疗的意义,以实现对每个患者的最大治疗反应,同时减少治疗的副作用。
关键词: 共识分子亚型,大肠癌,化疗,癌变,染色体不稳定,微卫星不稳定。
图形摘要
Current Drug Targets
Title:Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer
Volume: 19 Issue: 15
关键词: 共识分子亚型,大肠癌,化疗,癌变,染色体不稳定,微卫星不稳定。
摘要: Colorectal cancer (CRC) is a heterogeneous disease entity in terms of both molecular carcinogenesis and morphologic carcinogenesis multistep pathways. Considerable heterogeneity exists within CRC due to the varied genetic and epigenetic mechanisms involved in different carcinogenesis pathways. A better understanding of pathophysiology of tumors is necessary to develop modern and successful means of treatment in metastatic CRC. Over the last 5 years, there has been a surge in interest in the molecular classification of colorectal cancer, as its clinical importance both for predicting prognosis and in guiding personalized treatment had been acknowledged. Recently, the Colorectal Cancer Subtyping Consortium identified four consensus molecular subtypes, CMS 1-4 in CRC; however, attempts to stratify CRC using molecular features for prognostic and predictive purposes in clinical conditions had limited success. In this review, we focused on molecularly defined subtypes of CRC including specific mutations and discuss implications for current and future patient management in metastatic CRC to achieve the maximal therapeutic response for each patient, while reducing adverse side effects of therapy.
Export Options
About this article
Cite this article as:
Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer, Current Drug Targets 2018; 19 (15) . https://dx.doi.org/10.2174/1389450119666180803122744
DOI https://dx.doi.org/10.2174/1389450119666180803122744 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Growth Inhibition of Human Non-Small Lung Cancer Cells H460 By Green Tea and Ginger Polyphenols
Anti-Cancer Agents in Medicinal Chemistry Spermine Metabolism and Anticancer Therapy
Current Cancer Drug Targets Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Netrin and DCC: Axon Guidance Regulators at the Intersection of Nervous System Development and Cancer
Current Drug Targets Characterization of Molecular Alterations of BRCA1/2: Analysis and Interpretation Guidelines
Current Women`s Health Reviews Fluorescein-Inspired Near-Infrared Chemodosimeter for Luminescence Bioimaging
Current Medicinal Chemistry Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review
Current Bioactive Compounds Valeriana jatamansi Constituent IVHD-valtrate As a Novel Therapeutic Agent to Human Ovarian Cancer: in vitro and in vivo Activities and Mechanisms
Current Cancer Drug Targets The Role of DNA Methylation in the Pathogenesis and Treatment of Cancer
Current Clinical Pharmacology The Anticancer Role of Omega-3 Polyunsaturated Fatty Acids was Closely Associated with the Increase in Genomic DNA Hydroxymethylation
Anti-Cancer Agents in Medicinal Chemistry Probiotics in Intestinal and Non-Intestinal Infectious Diseases – Clinical Evidence
Current Pharmaceutical Design Structural Basis for Therapeutic Intervention of uPA/uPAR System
Current Drug Targets Yeast-Derived β-Glucan in Combination with Anti-Tumor Monoclonal Antibody Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery The Use of Fas Ligand, TRAIL and Bax in Gene Therapy of Prostate Cancer
Current Gene Therapy Current and Future Clinical Strategies in Colon Cancer Prevention and the Emerging Role of Chemoprevention
Current Pharmaceutical Design Trimethylamine N-oxide (TMAO) as a New Potential Therapeutic Target for Insulin Resistance and Cancer
Current Pharmaceutical Design Editorial[Hot Topic:Applications of Topological Indices and Complex Networks in Bioinformatics(Guest Editor: Humberto Gonzalez-Diaz)]
Current Bioinformatics A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry